Seeking Alpha

BioMimetic Therapeutics (BMTI) tanks in the post-trading session after the FDA says its proposed...

BioMimetic Therapeutics (BMTI) tanks in the post-trading session after the FDA says its proposed bone-graft device, Augment, wouldn't be approved without more information from previous studies. The company says it plans to submit the necessary information by the middle of the year. Shares -10.7% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|